Allogene Therapeutics (NASDAQ:ALLO) is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic chimeric antigen receptor T-cell (CAR T) therapies. Established in 2018 as a spinout from Kite Pharma, the company aims to deliver “off-the-shelf” cell therapies to patients with hematologic malignancies and solid tumors. By leveraging gene-editing technologies, Allogene seeks to overcome limitations associated with autologous CAR T treatments, such as manufacturing delays and variability.
The company’s pipeline includes multiple investigational allogeneic CAR T candidates targeting antigens like CD19 and BCMA, among others. These product candidates are designed to expand access to cell therapies by enabling rapid dosing without the need for patient-specific cell collection. Allogene has advanced several programs into clinical trials, exploring safety, efficacy, and persistence in various blood cancers and solid tumor indications.
Allogene’s operations are headquartered in South San Francisco, California, where it maintains research, development, and manufacturing facilities. The company has established collaborations with academic institutions and industry partners to enhance its gene-editing platforms and address key challenges in cell therapy production. These strategic alliances seek to streamline manufacturing processes and support global clinical development.
Under the leadership of Chief Executive Officer David Chang, Allogene’s executive team brings extensive experience in oncology, cell therapy, and biotech commercialization. The board of directors and scientific advisory committees include leaders from leading research institutions and pharmaceutical companies. Together, they guide the company’s efforts to deliver innovative allogeneic CAR T solutions and expand patient access to transformative cancer treatments.
